Here are some partnered drug dates that i was able to find:
Anetumab rav Ph2 nov 2017 primary completion date
SAR566658 ph 1 completes this month, but i believe results were presented in Oct.
Indatuximab ravt Ph 1/2 Nov '17 est primary completion date
LY3076226 aug '17 primary completion date
Cytomex..cx2009..IND filing 2017.
I think you are right, nothing to move stock unless there is unexpected results somewhere along the line. I think that finance/cash levels or + milestone surprises or other business issues would be more likely to move the stock than any biological consideration.